Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
43.99
+0.29 (+0.66%)
Official Closing Price
Updated: 7:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
7 Stocks Primed for a Spectacular Comeback in 2024
January 03, 2024
Although the usual suspects may carry confidence, these underappreciated comeback stocks might deliver the goods in 2024.
Via
InvestorPlace
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
January 03, 2024
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely...
Via
Benzinga
3 Strong Dividend Stocks to Buy Early On in 2024
January 03, 2024
The markets are always looking forward, and you should, too. Here are three dividend stocks to buy now.
Via
The Motley Fool
Bristol-Myers Squibb Company (NYSE: BMY) Making Surprising Moves in Tuesday Session
January 02, 2024
Via
Investor Brand Network
Exposures
COVID-19
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
January 02, 2024
From
Bristol Myers Squibb
Via
Business Wire
Analyst Expectations For Bristol-Myers Squibb's Future
December 27, 2023
Via
Benzinga
MarketBeat Week in Review: 12/25 - 12/29
December 30, 2023
The Santa Claus rally took the S&P 500 up about 0.75%, but recession concerns linger as the full impact of the Fed's rate hikes hasn't hit the economy.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
Interest Rates
US Equities
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
December 29, 2023
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via
Benzinga
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
December 29, 2023
The major indexes boast big annual gains with the Dow at record highs.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
After A Bruising 2023, Bristol-Myers Squibb Forges A Risky M&A Strategy
December 27, 2023
Via
Talk Markets
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
December 26, 2023
Via
Benzinga
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch
December 28, 2023
On Wednesday, Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy...
Via
Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
December 28, 2023
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the...
Via
Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
December 27, 2023
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.
Via
InvestorPlace
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
December 27, 2023
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole...
Via
Benzinga
Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
December 27, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
December 26, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst
December 26, 2023
H.C.
Via
Benzinga
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
December 26, 2023
Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.
Via
Investor's Business Daily
Why Is RayzeBio (RYZB) Stock Up 100% Today?
December 26, 2023
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024.
Via
InvestorPlace
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
December 26, 2023
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of <
Via
Benzinga
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023
From
Rayzebio, Inc.
Via
GlobeNewswire
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
December 25, 2023
Via
Benzinga
Bristol-Myers Buying Karuna Signals A Biotech Boom Ahead: Jefferies
December 24, 2023
Bristol-Myers Squibb is buying Karuna Therapeutics for $14 billion. Karuna Therapeutics Inc stock jumped nearly 50% on Friday. Jefferies analyst Michael Yee shares his view on biotech stocks.
Via
Talk Markets
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
December 24, 2023
These two biotech stocks could be poised for a trend reversal.
Via
The Motley Fool
What To Do With High-Flying Tech At The Start Of 2024?
December 23, 2023
Here, I will do two things. First, I will look at the macro backdrop at the start of 2024, and secondly I will run through the portfolio, how it is doing, and what changes I have made, or intend to...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.